Buy Biogen, as stock looks 'too good to ignore,' Wells Fargo says

A Biogen facility in Cambridge, Massachusetts.
Brian Snyder | Reuters

Investors are underestimating a new Alzheimer's drug from Biogen and some of the company's other key businesses, according to Wells Fargo.

More In Street Calls

CNBC ProHere are Friday's biggest analyst calls of the day: Amazon, Apple, Salesforce, Costco, Block & more
CNBC ProSalesforce is too cheap to ignore despite possible slower growth, JPMorgan says
CNBC ProRide out the market storm with Apple, Wedbush's Dan Ives says